Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. [electronic resource]
Producer: 20050711Description: 471-5 p. digitalISSN:- 0954-6928
- Abciximab
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal -- therapeutic use
- Biomarkers -- blood
- C-Reactive Protein -- metabolism
- CD40 Ligand -- blood
- Coronary Disease -- blood
- Enzyme-Linked Immunosorbent Assay
- Eptifibatide
- Female
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Inflammation -- blood
- Inflammation Mediators -- blood
- Interleukin-1 -- blood
- Interleukin-6 -- blood
- Interleukins -- blood
- Male
- Middle Aged
- Peptides -- therapeutic use
- Platelet Aggregation Inhibitors -- administration & dosage
- Postoperative Period
- Prospective Studies
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.